首页 | 本学科首页   官方微博 | 高级检索  
     

熊去氧胆酸治疗慢性乙肝及肝硬化伴胆汁淤积
引用本文:蒋孝华,蔡亚平,李小芬,雷创,刘玲玲,李映菊. 熊去氧胆酸治疗慢性乙肝及肝硬化伴胆汁淤积[J]. 南华大学学报(医学版), 2010, 38(1): 87-89
作者姓名:蒋孝华  蔡亚平  李小芬  雷创  刘玲玲  李映菊
作者单位:1. 南华大学,第一附属医院,感染科,湖南,衡阳,421001
2. 南华大学,流行病学教研室
摘    要:目的观察熊去氧胆酸(优思弗)治疗慢性乙肝及肝硬化伴胆汁淤积的疗效及安全性。方法将慢性乙肝及肝硬化伴胆汁淤积患者67例随机分为治疗组35例与对照组32例;治疗组在对照组内科治疗基础上加用优思弗胶囊,每次250 mg,每日3次,疗程12周。结果治疗12周后,优思弗治疗组总有效率为85.7%,显著高于对照组的59.4%(P<0.05);谷丙转氨酶(ALT)从145.5±80.4 U/L下降至47.3±35.6 U/L,总胆红素(TBIL)从96.9±37.2μmol/L下降至37.9±37.5μmol/L,直接胆红素(DBIL)从66.4±27.5μmol/L下降至21.9±26.1μmol/L,总胆汁酸(TBA)从78.7±33.1μmol/L下降至27.7±36.0μmol/L,碱性磷酸酶(ALP)从138.1±30.4 U/L下降至76.5±56.5 U/L,γ-谷氨酰转肽酶(γ-GT)从167.0±44.6 U/L下降至84.3±72.8 U/L,与对照组比较差异有统计学意义(P<0.01或P<0.05)。优思弗治疗组不良反应发生率为5.71%(2/35)。结论优思弗治疗慢性乙肝及肝硬化伴胆汁淤积患者有较好...

关 键 词:慢性乙型肝炎  肝硬化  胆汁淤积  熊去氧胆酸  

Ursodeoxycholic Acid on Patients of Chronic Hepatitis B and Hepatitis B Related Cirrhosis With Cholestasis
JIANG Xiao-hu,CAI Ya-ping,LI Xiao-fen,et al. Ursodeoxycholic Acid on Patients of Chronic Hepatitis B and Hepatitis B Related Cirrhosis With Cholestasis[J]. Journal of Nanhua University(Medical Edition), 2010, 38(1): 87-89
Authors:JIANG Xiao-hu  CAI Ya-ping  LI Xiao-fen  et al
Affiliation:Department of Infection;the First Affiliated Hospital of University of South China;Hengyang;Hunan 421001;China
Abstract:Objective To assess the efficacy and safty of ursodeoxycholic acid(UDCA)in treatment of chronic hepatitis B and hepatitis B related cirrhosis with intrahepatic cholestasis. Methods Sixty-seven chronic hepatitis B and hepatitis B related cirrhotic patients with cholestasis were randomly divided into the UDCA group(n=35) and the control group(n=32).The UDCA group was given oral capsule of UDCA,250 mg three times daily for 12 weeks besides basic therapy.The control group was only treated with conventional ther...
Keywords:hepatitis B  chronic  liver cirrhosis  cholestasis  ursodeoxycholic acid  
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《南华大学学报(医学版)》浏览原始摘要信息
点击此处可从《南华大学学报(医学版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号